
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company.
iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company. This study will utilize iCardiac’s Rapid QT service offering, which assists trial sites in making accurate patient inclusion/exclusion decisions.
Read the full release






